泌尿外科技术经济评估中的健康相关生活质量与患者报告结局:挑战与机遇
本文为叙述性综述,探讨健康相关生活质量(HRQoL)评估与患者报告结局测量(PROMs)在泌尿外科干预经济评估中的作用。综述综合经济评估框架、效用推导方法,并批判性评价通用与疾病特异性PROMs的应用,证据来自主要泌尿外科试验与模型评估。结论认为HRQoL与PROMs是价值导向泌尿外科护理的基础,未来需开发基于偏好的泌尿外科特异性PROMs、改进电子化采集、验证映射算法并将手术相关PROMs纳入经济评估。
要点
- PROMs支撑泌尿外科全病种的成本-效用分析,但通用工具对泌尿症状敏感性不足。
- 疾病特异性工具提供细粒度信息,但常需映射至效用值,引入不确定性。
- 试验来源的PROMs衍生的QALY差异可 decisive 影响成本-效果结论。
核心结论
- HRQoL与PROMs是价值导向泌尿外科护理的基础。
- 准确且情境敏感测量确保成本-效用分析反映患者体验与临床结局。
- 未来优先事项包括开发基于偏好的泌尿外科特异性PROMs、改进数字化/电子PROM采集、验证映射算法并将手术相关PROMs纳入经济评估。
研究设计与样本
- 叙述性综述,综合泌尿外科经济评估关键框架,描述效用推导方法,批判性评价通用与疾病特异性PROMs的应用。
- 证据来自主要泌尿外科试验与模型评估,关注其对卫生技术评估决策的影响。
主要发现
- PROMs支撑BPH、尿失禁、膀胱过度活动症、膀胱癌、肾癌和前列腺癌等全谱泌尿外科疾病的成本-效用分析。
- 通用工具如EQ-5D和SF-36便于跨疾病比较,但可能对泌尿症状缺乏敏感性。
- 疾病特异性工具如IPSS、OAB-q、EPIC-26提供细粒度信息,但常需映射至效用值,引入不确定性。
- 试验来源评估(TRIUMPH、SIMS、ROSETTA)表明PROMs衍生的QALY差异可决定性影响成本-效果。
- 手术相关PROMs如CARE measure可捕获通用工具未测量的重要短期恢复结局。
临床怎么用
- 在经济评估中应重视PROMs选择,平衡通用工具跨病种可比性与疾病特异性工具对泌尿症状的敏感性。
- 将PROMs衍生的QALY差异纳入成本-效用分析,以反映患者体验与临床结局。
- 考虑整合手术相关PROMs(如CARE measure)以捕获短期恢复结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the role of health-related quality of life (HRQoL) assessments and patient-reported outcome measures (PROMs) in the economic evaluation of urological interventions, highlighting methodological challenges, and identifying areas for future development. METHODS: This narrative review synthesises key frameworks for economic evaluation in urology, describes methods for utility derivation, and critically appraises the application of both generic and disease-specific PROMs. Evidence is drawn from major urological trials and model-based evaluations, with attention to their impact on health technology assessment decisions. RESULTS: Patient-reported outcome measures underpin cost-utility analyses across the full spectrum of urological conditions, including benign prostatic hyperplasia (BPH), urinary incontinence, overactive bladder, bladder cancer, renal cancer, and prostate cancer. Generic instruments such as the EuroQoL five Dimensions (EQ-5D) and 36-item Short-Form Health Survey (SF-36) facilitate cross-disease comparison but may lack sensitivity to urological symptoms. Disease-specific tools (e.g., International Prostate Symptom Score, Overactive Bladder Questionnaire, 26-item Expanded Prostate cancer Index Composite) provide granularity but often require mapping to utility values, introducing uncertainty. Trial-based evaluations (e.g., Trans European Research into the use of Management Policies for LUTS suggestive of BPH in Primary Healthcare [TRIUMPH], Single-Incision Mini-Slings [SIMS], Refractory Overactive Bladder: Sacral NEuromodulation vs BoTulinum Toxin Assessment [ROSETTA]) demonstrate that PROM-derived quality-adjusted life year differences can decisively influence cost-effectiveness. Surgery-related PROMs including the Consultation and Relational Empathy measure can capture important short-term recovery outcomes not measured by generic tools. CONCLUSIONS: Health-related quality of life and PROMs are foundational to value-based urological care. Accurate and context-sensitive measurement ensures that cost-utility analyses reflect patient experience as well as clinical outcomes. Future priorities include development of preference-based urology-specific PROMs, improved digital/electronic PROM capture, validation of mapping algorithms, and integration of surgery-related PROMs into economic evaluations.
引用
- Bahnasawi ME, Moss C, Kinsella N, et al. Health-related quality of life and patient-reported outcome measures in economic evaluation of urological technologies: challenges and opportunities. BJU Int. 2026. PMID: 42381123. doi:10.1111/bju.70365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。